Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-P2-COVID
jRCT2071200041Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Adrenomedullin with Placebo (2 arms). Primary endpoint: Period of mechanical ventilation. Started Nov 2020; status: recruiting.
02
Drugs
fispemifene
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200041.